Qualigen Therapeutics, Inc.
QLGN
$1.97
$0.073.68%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 102.73% | -1,086.55% | |||
| Gross Profit | -102.73% | 1,086.55% | |||
| SG&A Expenses | 145.04% | -11.11% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 159.78% | -23.30% | |||
| Operating Income | -159.78% | 23.30% | |||
| Income Before Tax | -211.20% | 52.66% | |||
| Income Tax Expenses | -100.00% | 350.00% | |||
| Earnings from Continuing Operations | -209.21% | 52.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -209.21% | 52.30% | |||
| EBIT | -159.78% | 23.30% | |||
| EBITDA | -- | 23.32% | |||
| EPS Basic | -66.76% | 76.81% | |||
| Normalized Basic EPS | -204.84% | 89.89% | |||
| EPS Diluted | -66.76% | 76.81% | |||
| Normalized Diluted EPS | -204.84% | 89.89% | |||
| Average Basic Shares Outstanding | 85.40% | 102.55% | |||
| Average Diluted Shares Outstanding | 85.40% | 102.55% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||